Jury Hits Novartis With $178M Verdict In Drug Patent Fight
A California federal jury hit Novartis with a $177.8 million verdict Thursday for selling a skin cancer drug that infringes two patents owned by a Daiichi Sankyo subsidiary, rejecting Novartis' arguments...To view the full article, register now.
Already a subscriber? Click here to view full article